Cancer is one of the leading causes of morbidity worldwide. For years, numerous research studies have been conducted to stop this catastrophic disease. Today, with the advancing treatment options, it has become possible to combat this deadly disease to some extent. Next-generation sequencing helps in the detection of circulating tumor DNA. In addition, the robotic platform is a new tool to help in fighting lung cancer. Advancements in technology are helping physicians in better diagnosis and understanding hard to treat tumors with precision.
Global capecitabine market is segmented by application and drug formulation.
By application, the market is segmented into colon cancer, rectal cancer, breast cancer, gastric cancer, and others. Breast cancer is projected to dominate the global market in the years to come as Capecitabine is one of the cost-effective and major treatments used globally.
Based on drug formulation, the capecitabine market is segmented into tablets and capsules. The tablets segment is expected to lead the market in line with its high absorbability in the bloodstream.
Geographically, the global capecitabine market is segmented into four regions: the Americas, Europe, Asia Pacific, and the Middle East & Africa (MEA).
Got questions about your regional growth of
Just drop us a line or call on +1 646 480 7505
With the increasing prevalence of cancer and high spending on healthcare, the Americas is expected to lead the global market. Breast cancer poses a major cause of morbidity in the U.S. It has been found that 1 in 8 women develops breast cancer in the U.S. In addition, increasing resistance to aggressive treatments has boosted the demand for novel therapeutic drugs such as capecitabine in the region.
Europe is the second largest market globally. As per EU reports, cancer is one of the leading cause of deaths in the region. There is a requirement of an effective and accessible health system to handle the situation. Several policies have been made to fight against cancer, such as the banning of tobacco products and implementation of population-based screening, which further helps in early detection of different cancers such as breast, cervical, and colorectal.
Asia Pacific is witnessing growing awareness regarding prevention of all cancers as a result of increasing screening approaches and clinical trials in the region. Increasing collaboration with international organizations is also strengthening the research activities in the region. For instance, India and the U.K. have collected 10 million pounds to address the challenges of affordable and preventable cancer treatment.
MEA is expected to witness steady growth. Today, rising prevalence of breast cancer in the Middle East countries is a major concern. Despite major efforts taken for early detection, the number is still on the rise. This can be attributed to the poor quality of life of women, and lack of Education and favorable socio-economic conditions. Moreover, improving health care conditions are expected help in the diagnosis, such as mobile mammography units and family health care programs.
Some of the key players in the global capecitabine market are Fresenius SE & Co. KGaA (Germany), Genentech, Inc. (U.S.), Dr Reddy Laboratories Ltd. (India), Cipla Inc. (India), Accord Healthcare Ltd. (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Teva Pharma B.V., Sandoz Inc. (U.S.), Zentiva N.V. (Netherlands), and Ranbaxy Laboratories Ltd. (India).
Capecitabine Market Segmentation
By Drug Formulation